April 16, 2012. In this letter, NCHR and other women’s organizations urge the FDA to not approve Qnexa, a weight loss drug, because of serious unresolved safety concerns about its potential to cause cardiovascular harm and birth defects.
Read More »On Medical Treatments & Products
Comment on a FDA Guidance on the Evaluation of Sex Differences in Medical Device Clinical Studies
March 19, 2012. The National Research Center for Women and Families has been a long-time advocate of medical device clinical studies including data on safety and effectiveness for women. In this comment letter to the FDA, we describe the importance of analyzing data for women separately and how this information should be used to help women and providers make the best informed decisions.
Read More »Letter to Dr. Hamburg, FDA Commissioner on the Review of Drospirenone (DRSP)-Based Oral Contraceptives
March 9, 2012. When oral contraceptives first became available, comparing risks and benefits of oral contraceptives to pregnancy was the right question.
Read More »NCHR Testimony on Classification for Cranial Electrotherapy Stimulators
February 10, 2012. This testimony supported the FDA’s position that the available scientific evidence does not support reclassifying Cranial Electrotherapy Stimulators to a medical device category with lower risk.
Read More »FDA Needs to Provide Breast Implant Patients and Physicians with Unreported Industry Data About Quality of Life, Connective Tissue Symptoms, Rupture Rates Per Patient, and Other Complications
January 5, 2012. At the FDA Advisory Panel meetings in 2003 and 2005, FDA provided and presented data from the Breast Implant Core studies regarding connective tissue disorder (CTD) signs and symptoms (S/S) and Quality of Life measures.
Read More »